AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05480332 — intervention group
Intervention type: DEVICE
Intervention: EndoPAT
Description: We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point.
Study NCT04328363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
Study NCT05689086 — intervention group
Intervention type: OTHER
Intervention: Virtual Heart Failure Optimization Program
Description: Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming.
Study NCT02952911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone and Smartwatch
Description: Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
Study NCT02952911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone and Smartwatch
Description: Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
Study NCT03181126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: tablet
Study NCT03181126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
Study NCT03181126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet
Study NCT01708889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)
Study NCT02352662 — intervention group
Intervention type: OTHER
Intervention: Perioperative blood samples collection
Description: Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
Study NCT00289237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study NCT04569968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Description: For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
Study NCT02763332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper trunk group (UTG)
Description: This bandage was placed over the upper trapezius muscle.
Study NCT02763332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global trunk group (GTG)
Description: This bandage was placed globally along the back
Study NCT03357575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells from adipose
Description: inject mesenchymal Stem Cells from adipose
Study NCT03357575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: inject hyaluronic acid
Study NCT03071731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.
Study NCT02300337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduce Cuff pressure
Description: We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
Study NCT04691882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic contraction
Description: Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
Study NCT04691882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphagmatic relaxation
Description: Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
Study NCT03963323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine Sulfate/Chondroitin Sulfate Tablet
Description: Given PO
Study NCT03963323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00505726 — intervention group
Intervention type: PROCEDURE
Intervention: Reflectance Confocal Imaging
Description: Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
Study NCT00273351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]B-CIT
Description: Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
Study NCT01802476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Drug Formulation of PD-0332991
Description: Treatment A consists of a single 125 mg oral dose of PD-0332991.
Study NCT03488290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus TF-CBT
Description: Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
Study NCT03488290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The Treatment as Usual group will receive routine care
Study NCT03488290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The Treatment as Usual group will receive routine care
Study NCT03906513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMK2
Description: OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
Study NCT03906513 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OMK2
Description: OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
Study NCT03938064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prontogest 400 mg vaginal pessaries
Description: natural progesterone in the form of vaginal suppositories 400 mg
Study NCT03938064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prontogest 400 mg vaginal pessaries
Description: natural progesterone in the form of vaginal suppositories 400 mg
Study NCT02762383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2
Description: Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
Study NCT00586079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation surgery.
Description: Deep brain stimulation surgery.
Study NCT02040987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: AZD3293 oral solution - one single dose (low dose).
Study NCT02040987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: AZD3293 oral solution - one single dose (high dose).
Study NCT02040987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution - one single dose
Study NCT02040987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin tablet - one single dose
Study NCT03806465 — intervention group
Intervention type: OTHER
Intervention: Feasibility survey
Description: A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
Study NCT03806465 — intervention group
Intervention type: OTHER
Intervention: Sentinel hospital surveillance
Description: Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
Study NCT01802476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Formulation of PD-0332991
Description: Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
Study NCT00392314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT post 2 cycles of chemotherapy
Description: sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
Study NCT03806465 — intervention group
Intervention type: OTHER
Intervention: Community mortality surveillance
Description: A verbal autopsy will be performed
Study NCT02755454 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Perfusion CT Imaging
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine HCL (M016455)
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine HCL (M016455)
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pseudoephedrine
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT03703141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucralose 48 mg (splenda)/day for ten weeks
Description: volunteers will take sucralose or placebo daily for 70 days
Study NCT03703141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose 48 mg (splenda)/day for ten weeks
Description: volunteers will take sucralose or placebo daily for 70 days
Study NCT02057302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuezhikang capsule
Study NCT00804414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBG
Description: Solution for topical use
Study NCT00804414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Solutin for topical use
Study NCT01705951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Description: Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
Study NCT01705951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
Study NCT01561885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pathway-Based Care
Description: Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
Study NCT00359385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 70mg weekly
Description: 70mg weekly
Study NCT00359385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate 70mg weekly
Description: 70mg weekly
Study NCT03739333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-Methionine PET-MRI
Description: Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
Study NCT02003664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen ER
Description: Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
Study NCT02003664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
Study NCT04506359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
Study NCT00385697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV dosing for 14 days, repeated at Week 26
Study NCT00385697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily IV dosing for 14 days, repeated at Week 26
Study NCT01811628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion taking about 10-15 minutes.
Study NCT01811628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audio-recorded interview that will last about 1 hour.
Study NCT01909947 — intervention group
Intervention type: OTHER
Intervention: Cardiorespiratory signal acquisition
Description: Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant
Study NCT04659200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing.
Description: For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
Study NCT01705223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: 4mg/dose, three doses at week 0,4,8
Study NCT01705223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine prime with the addition of electroporation
Description: 4mg/dose, three doses at week 0,4,8
Study NCT01705223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 16
Study NCT01705223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 24
Study NCT01705223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTV boost
Description: at week 32
Study NCT01325818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin, rosuvastatin
Description: 1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day
Study NCT03071731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bronchodilators
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.
Study NCT03071731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Administration of a nebulized placebo before the administration of a functional test
Study NCT03071731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of a nebulized placebo before the administration of a functional test
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)
Description: First line regimen
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)
Description: First line regimen
Study NCT01306721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
Description: First line regimen
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d4T/3TC/ABC (stavudine/lamivudine/abacavir)
Description: First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)
Description: Second line regimen
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)
Description: Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
Study NCT00427297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
Description: First line regimen
Study NCT04989634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary and weight management
Description: health education , nutritional analysis and individualized dietary guidance
Study NCT04989634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard prenatal education on diet, nutrition and physical activity
Study NCT04018040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-ovo vegetarian diet
Description: Lacto-ovo vegetarian diet inclusive of dairy and eggs
Study NCT02160522 — intervention group
Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
Study NCT02106663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential Pulmonary Vein Ablation
Description: Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
Study NCT02106663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Pulmonary Vein Isolation
Description: Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.